Technical Specification Sheets
Vertical 10.5 mm TSE 40:1 (L/D) for Pharma applications
Specification sheet for the Vertical 10.5 mm Twin-Screw Extruder 40:1 (L/D) (Pharma applications)
Horizontal 21 mm TSE 40:1 (L/D) for Pharma applications
Specification sheet for the Horizontal 21 mm Twin-Screw Extruder 40:1 (L/D) (Pharma applications)
Horizontal 21 mm TSE 40:1 (L/D) for Battery / R&D applications
Specification sheet for the Horizontal 21 mm Twin-Screw Extruder 40:1 (L/D) (Battery / R&D applications)
Horizontal 21 mm TSE 30:1 (L/D)
Specification sheet for the Horizontal 21 mm Twin-Screw Extruder 30:1 (L/D)
_edited_edited.jpg)
Horizontal 10.5 mm TSE 40:1 (L/D)
Specification sheet for the Horizontal 10.5 mm Twin-Screw Extruder 40:1 (L/D)
Horizontal 10.5 mm TSE 25:1 (L/D)
Specification sheet for the Horizontal 10.5 mm Twin-Screw Extruder 25:1 (L/D)
Downloads
All our specification sheets and research papers, in one place
Research Papers
Hot Melt Extruded Amorphous Solid Dispersions containing Lumefantrine and Soluplus
Poster presented at AAPS PharmSci 360 2024 Salt Lake City, on joint research with Queen's University Belfast on Lumefantrine prior to publishing our full paper
Hot Melt Extruded High-Dose Amorphous Solid Dispersions Containing Lumefantrine and Soluplus
Over the last 15 years, a small number of paediatric artemisinin-based combination therapy products have been marketed. These included Riamet® and Coartem® dispersible tablets, a combination of artemether and lume fantrine, co-developed by the Medicines for Malaria Venture and Novartis. Disappointingly, patient compliance, requirement for high-fat meal, and sporadic drug dissolution behaviours following administration still result in considerable challenges for these products. (Joint research between Rondol and Queens' University Belfast)
Improving Active Pharmaceutical Ingredient Formulation by Hot Melt Extrusion
Poster presented at PBP Vienna in 2024, prior to the publication of our paper on Lumefantrine.
Extrusion for Pharma Applications—An update
This paper aims to give an overview of our current research and development on hot-melt extrusion (HME) for pharmaceutical formulation and drug delivery. Unfortunately, a large percentage of marketed drugs (40%) and those in the development pipeline (90%) are poorly water soluble. We use a few examples to show that solubility of APIs can be drastically improved by using HME to mix them with different biocompatible polymers and playing with the various process parameters (extrusion temperature, screw speed, screw configuration, etc.).
Vertical Hot Melt Extrusion—A cutting-edge technology for personalized and sustainable food systems
New trends in the food industry are radically transforming how we produce, process, and consume food, creating new pathways for personalization, sustainability, and operational efficiency. Vertical Hot Melt Extrusion (HME) is a major innovation that offers unprecedented opportunities to create highly personalized food products tailored to specific dietary needs or remote locations, including nutrient-dense options designed for individual health requirements.